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Modeling Treatment Response for Lamin A/C Related Dilated
Cardiomyopathy in Human Induced Pluripotent Stem Cells
Yee-Ki Lee, PhD;* Yee-Man Lau, PhD;* Zhu-Jun Cai, MSc; Wing-Hon Lai, PhD; Lai-Yung Wong, BSc; Hung-Fat Tse, MD, PhD; Kwong-Man Ng,
PhD; Chung-Wah Siu, MD
Background-—Precision medicine is an emerging approach to disease treatment and prevention that takes into account individual
variability in the environment, lifestyle, and genetic makeup of patients. Patient-speciﬁc human induced pluripotent stem cells hold
promise to transform precision medicine into real-life clinical practice. Lamin A/C (LMNA)-related cardiomyopathy is the most
common inherited cardiomyopathy in which a substantial proportion of mutations in the LMNA gene are of nonsense mutation.
PTC124 induces translational read-through over the premature stop codon and restores production of the full-length proteins from
the affected genes. In this study we generated human induced pluripotent stem cells-derived cardiomyocytes from patients who
harbored different LMNA mutations (nonsense and frameshift) to evaluate the potential therapeutic effects of PTC124 in LMNA-
related cardiomyopathy.
Methods and Results-—We generated human induced pluripotent stem cells lines from 3 patients who carried distinctive
mutations (R225X, Q354X, and T518fs) in the LMNA gene. The cardiomyocytes derived from these human induced pluripotent
stem cells lines reproduced the pathophysiological hallmarks of LMNA-related cardiomyopathy. Interestingly, PTC124 treatment
increased the production of full-length LMNA proteins in only the R225X mutant, not in other mutations. Functional evaluation
experiments on the R225X mutant further demonstrated that PTC124 treatment not only reduced nuclear blebbing and electrical
stress-induced apoptosis but also improved the excitation-contraction coupling of the affected cardiomyocytes.
Conclusions-—Using cardiomyocytes derived from human induced pluripotent stem cells carrying different LMNA mutations, we
demonstrated that the effect of PTC124 is codon selective. A premature stop codon UGA appeared to be most responsive to
PTC124 treatment. ( J Am Heart Assoc. 2017;6:e005677. DOI: 10.1161/JAHA.117.005677.)
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L amins A and C (Lamin A/C) are intermediate ﬁlamentproteins encoded by the autosomal LMNA gene and
constitute major components of the nuclear lamina.1 Muta-
tions in LMNA cause a wide spectrum of human diseases
collectively referred to as “laminopathies,”2-6 from multisys-
tem involvement conditions such as Hutchinson Gilford
progeria and muscular dystrophy to isolated dilated
cardiomyopathy. LMNA-related cardiomyopathy is character-
ized by early-onset atrioventricular block and atrial ﬁbrillation
and subsequently progresses to ventricular tachyarrhythmia
with consequent sudden cardiac death, left ventricular
dysfunction, and heart failure. LMNA mutations are the most
common cause of familial dilated cardiomyopathy, accounting
for 5% to 10% of all cases and up to 30% to 45% of families
with dilated cardiomyopathy and conduction system dis-
ease.7,8 Despite a clear genetic basis, to date, no speciﬁc
therapeutic strategies are available to modify the disease
progression. In fact, the clinical management of LMNA-related
dilated cardiomyopathy is no different from that for other
forms of dilated cardiomyopathy. Genetically, LMNA-related
cardiomyopathy is a dominant trait, and based on the results
of mouse model, haploinsufﬁciency is likely the pathogenic
mechanism.9 One important implication of nonsense muta-
tions is a therapeutic possibility of alleviating or even
reversing the disease process by translational read-through
of premature stop codons and production of full-length
proteins by interfering with ribosomal proofreading. For
instance, PTC124, also known as ataluren, discovered through
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high-throughput screening utilizing premature UGA luciferase
reporters to promote read-through of the premature stop
codon,10-12 has been granted orphan drug designation by the
Food and Drug Administration in the United States for the
treatment of nonsense mutation-related genetic disease. A
phase 3 clinical trial is ongoing to evaluate the clinical efﬁcacy
of PTC124 in patients with nonsense mutation cystic ﬁbrosis,
which accounts for around 10% of cystic ﬁbrosis cases.13
Notwithstanding the cost, standard randomized, double-
blind, placebo-controlled studies might not always be possible
because the number of patients with the same condition
harboring the same or similar mutation is usually small.
Human induced pluripotent stem cells (hiPSC) generated from
individual patients who harbor a speciﬁc mutation have been
exploited to elucidate the pathogenic mechanisms of various
cardiovascular diseases.14-19 The hiPSC technology is
expected to revolutionize the concept of precision medicine
by providing a steady supply of patient-speciﬁc functional
cells for preclinical testing in order to identify the most
effective and safest personalized strategies for a particular
individual.20 In fact, the US Food and Drug Administration has
recently examined ways in which hiPSC-derived cardiomy-
ocytes can be used in preclinical investigation of the potential
risks in metabolic pathways or proarrhythmia events. Using
hiPSC-derived cardiomyocytes generated from patients with
LMNA-related cardiomyopathy, we have previously demon-
strated that nuclear senescence and cell apoptosis are the
key pathophysiological factors in LMNA-related cardiomyopa-
thy.18 In the present study we generated iPSCs from 3
patients with documented LMNA-related cardiomyopathy
arising from 2 different nonsense mutations (UGA and UAG)
and a frame-shift mutation in the LMNA gene. We differen-
tiated them into cardiomyocytes to evaluate the effects of
PTC124 on lamin A/C protein production, nuclear senes-
cence, and cell apoptosis. Not only will our results allow us to
differentiate a PTC124 responder from nonresponder to enter
the clinical trials, but, more importantly, they demonstrate the
feasibility of this iPSC-based precision medicine approach in
studying genetic diseases.
Methods
Generation of hiPSC From Patients Carrying
Cardiomyopathy-Associated LMNA Mutations
The study protocol for procurement of human tissue for the
generation of hiPSCs was approved by the local Institutional
Review Board and was registered at the Clinical Trial Center,
the University of Hong Kong (IRB-UW08-258). After obtaining
written informed consent from all participants, we collected
skin biopsies. Skin biopsy samples were mechanically disso-
ciated and plated onto 6-well culture dishes with the culture
medium supplemented with 10% fetal bovine serum, as
previously described.21 Dermal ﬁbroblasts growing out from
the skin tissue were expanded and transduced with len-
tiviruses encoding human OCT4, SOX2, KLF4, and c-MYC.
Putative hiPSC clusters were typically observed at 14 to
21 days after lentiviral transduction and were manually
dissected and expanded onto new matrigel-coated 6-well
plates. The authenticity of the hiPSCs was conﬁrmed with the
expression of a panel of pluripotent markers, transgene
silencing, OCT4 promoter demethylation, and teratoma
formation after inoculation into severe combined immunod-
eﬁciency mice (data not shown). All stem cell characterization
works have been reported previously.21
Cardiac Differentiation
Cardiac differentiation of hiPSCs was induced using a
previously reported protocol.22 In brief, undifferentiated
hiPSCs were maintained in mTeSRTM1 medium (STEMCELL
Technologies Inc, Vancouver, BC, Canada). Four days before
induction, hiPSCs were dissociated into single cells with
accutase (Invitrogen, Carlsbad, CA) and then seeded onto a
12-well matrigel-coated plate (Thermo Scientiﬁc Inc, Waltham,
MA) supplemented with Y27632 (5 lmol/L) (Stemgent,
Cambridge, MA). On the ﬁrst induction day the culture
medium was switched to RPMI medium (Life Technologies,
Carlsbad, CA) without insulin and supplemented with B27 (Life
Technologies) and a GSK-b inhibitor, CHIR99021 (12 lmol/L)
(Selleckchem, Houston, TX), and refreshed 24 hours later. On
day 4, a Wnt signaling inhibitor, IWP2 (5 lmol/L) (Sel-
leckchem, Houston, TX), was added to the culture medium.
Typically, spontaneously beating cardiomyocytes were
Clinical Perspective
What Is New?
• This is the ﬁrst study of the read-through drug PTC124 in
patient human induced pluripotent stem cells-derived car-
diomyocytes for treatment of nonsense (UGA stop codon–
speciﬁc) related cardiac laminopathy by recovery of expres-
sion of full-length Lamin A/C.
What Are the Clinical Implications?
• This study demonstrates the potential feasibility of human
induced pluripotent stem cells-based precision medicine
approaches to predict clinical responses of dilated cardio-
myopathy patients and to study disease mechanisms.
• Drug testing in patient human induced pluripotent stem
cells-derived cardiomyocytes may be a possible approach to
select PTC124 responders for entry into clinical trials.
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observed around 9 days after induction. The cells were
maintained in the cardiomyocyte maintenance medium (RPMI
medium with B27 supplement) and used in subsequent
analyses.
LMNA-Related Cardiomyopathy Model
The hiPSC-based model of LMNA-related cardiomyopathy was
induced using electrical stimulation according to our previ-
ously published protocol.18 Speciﬁcally, hiPSC-derived car-
diomyocytes were seeded on 13-mm glass coverslips (Nunc
A/S, Rockilde, Denmark) and mounted on a 6-well plate ﬁlled
with corresponding medium. Electrical stimulation was then
delivered to the cultured cells for 4 hours with carbon
electrodes using an 8-channel C-Pace cell culture stimulator
(IonOptix Co, Milton, MA) at 6.6 V/cm, 1 Hz, 2 milliseconds
with alternating polarity. The total number of cells was
counted before and after electrical stimulation.23-25
PTC124 Treatment
A stock solution of PTC124 was prepared by dissolving the
lyophilized PTC124 (Selleckchem, Houston, TX) in DMSO to a
concentration of 10 mmol/L. The stock solution was diluted
in cell culture medium and preheated to 37°C to ensure
complete dissolution before being applied to the cells. To test
the potential therapeutic effects of PTC124, hiPSC-derived
cardiomyocytes were pretreated with PTC124 (50 lmol/L)
for 7 days before electrical stressing.
Western Blot Analysis
Western blot analysis was performed following the protocol
described previously.26 In brief, cells of interest were washed
with Dulbecco phosphate-buffered saline and lysed in RIPA
buffer (Cell Signaling Technology, Danvers, MA) containing
0.2% Triton X-100, 5 mmol/L EDTA, 1 mmol/L PMSF, 10 lg/
mL leupeptin, 10 lg/mL aprotinin with additional 100 mmol/
L NaF and 2 mmol/L Na3VO4. The supernatant was collected
after spinning for 20 minutes at 12 000g. The amount of
protein was quantiﬁed using a Bio-Rad protein assay kit
(Hercules, CA). For each sample, 50 lg of total protein was
resolved on a 4% to 12% Bis-Tris plus gel (Gibco, Gaithersburg,
MD) and transferred onto nitrocellulose membranes. After
blocking with 5% nonfat dry milk in TBS (pH 7.4) with 0.5%
Tween-20 at 4°C, the transferred protein was probed by
primary mouse monoclonal antibodies speciﬁc to lamin A/C
(clone 4C-11; 1:2000; Cell Signaling Technologies, Danvers,
MA). As an endogenous control, the levels of b-actin were
evaluated using a monoclonal antibody speciﬁc to b-actin. The
location of the immunoreactive protein complex was detected
with HRP-conjugated secondary antibodies (Cell Signaling
Technology, Danvers, MA; 1:2000) and visualized with stan-
dardized enhanced chemiluminescence systems.
Assessment of Nuclear Blebbing Events
At 30 to 40 days after induction of differentiation, hiPSC-
derived cardiomyocytes were dissociated by collagenase
treatment and subsequently seeded on gelatin-coated cover-
slips for immunostaining analysis and functional evaluation.
For immunostaining, cells were ﬁxed and permeabilized in 2%
paraformaldehyde for 20 minutes at 4°C and then washed
with wash buffer (Dulbecco phosphate-buffered saline with
0.1% Triton X-100; Sigma-Aldrich, St. Louis, MO). The nuclear
lamina of hiPSC-derived cardiomyocytes was visualized by
staining with antibodies speciﬁc to lamin A/C (clone 4C-11;
1:200; Cell Signaling Technologies, Danvers, MA) and cardiac-
speciﬁc markers such as goat anti-tropoinin-T (1:400; Abcam,
Cambridge, UK). Positively probed cells were visualized by
addition of rabbit anti–goat IgG H+L Alexa 594 and rabbit
anti–mouse IgG H+L Alexa 488 (Molecular Probes, Eugene,
OR) for 30 minutes. Images were acquired using a ﬂuores-
cence confocal Carl Zeiss LSM 700 microscope (Zeiss GmbH,
Gottingen, Germany).
Terminal Deoxynucleotidyl Transferase dUTP
Nick End Labeling Assay for Apoptosis
A terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay was performed using an in situ Cell
Death Detection Kit, Fluorescein (Roche Applied Sciences,
Mannheim, Germany) according to the manufacturer’s proto-
col. Cells were grown on glass coverslips, ﬁxed with 4%
paraformaldehyde, and permeabilized with 0.1% Triton X-100
in 0.1% sodium citrate for 2 minutes on ice. Cells were
incubated in TUNEL reaction mixture at 37°C for 60 minutes
in a humidiﬁed dark chamber. The TUNEL-labeled samples
were subjected to costaining with troponin-T antibodies for
conﬁrmation of cardiac identity. Coverslips were mounted
onto glycerol-based mountant. Images were acquired using a
Carl Zeiss ﬂuorescence microscope with AxioVision 6.0
software (Zeiss GmbH, Gottingen, Germany). The number of
apoptotic cells on electrical stimulation was further quantiﬁed
using the APO-BrdU TUNEL Assay Kit (Molecular Probes, Inc,
Eugene, OR). The dissociated cells were ﬁxed in 1% (w/v)
paraformaldehyde on ice for 15 minutes and then washed
twice with Dulbecco phosphate-buffered saline at 300g for
5 minutes. The ﬁxed cells were stored in ice-cold 70% (v/v)
ethanol at 20°C before the nicked end labeling reaction. The
cells were washed with wash buffer before incubation in
TUNEL labeling solution for an hour at 37°C (10 lL reaction
buffer, 0.75 lL TdT enzyme, 8 lL of BrdU, and 31.25 lL
dH2O). After further washing with rinse buffer, cells were
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stained with the Alexa Fluor 488 dye-labeled anti-BrdU
antibodies for a half-hour. The propidium iodide/RNase A
staining buffer was ﬁnally added to the cells before ﬂow
cytometry analysis. The positively labeled cells (green signal),
a population with DNA fragmentation, were counted as
percentage of apoptotic cells.
Taqman Assay for Quantiﬁcation of LMNA
Expression
Total RNA was extracted from ﬁbroblasts using TRIZOL reagent
following the procedure provided by the manufacturer (Life
Technologies, Carlsbad, CA). For each sample, 1 lg of total
RNA was used for cDNA synthesis using the QuantiTect
Reverse Transcription kit (Qiagen, Venlo, The Netherlands).
Taqman gene expression assay was carried out using a FAM-
labeled probe derived from the Universal Probe Library (lamin
A/C (LMNA): probe #66, troponin-T type 2 (TNNT2): probe #63
and a-tubulin (TUB4q): probe #75 (Roche Applied Sciences) in
combination with FastStart Universal Probe Master (Rox) as
the detection reagent (Roche Applied Sciences, Indianapolis,
IN). The samples were analyzed as duplicates on the
StepOnePlus real-time polymerase chain reaction system (Life
Technologies). TUBA4A served as a housekeeping gene for
normalization, and TNNT2 was used for normalization of
cardiac purity within the whole population.
Excitation-Contraction Coupling Analysis by
Simultaneous Calcium Imaging and Video Edge
Detection
To study the calcium-handling properties, hiPSC-derived
cardiomyocytes were loaded with Fura-2 AM (Life Technolo-
gies, Carlsbad, CA), a calcium indicator, at a working
concentration of 1 lM for 20 minutes. Unincorporated dye
was removed, and the cells were subsequently incubated in
Tyrode solution. For calcium transient measurements, ﬁeld-
stimulated electrical pacing was induced by the Myopacer EP
Field Stimulator (IonOptix, Westwood, MA) at 40 V cm1,
5-millisecond pulse duration at frequencies of 0.5 Hz, 1 Hz,
1.5 Hz, and 2 Hz. The calcium ﬂuorescence and video-edging
(contractile force) signal were simultaneously recorded by
MyoCam-S (IonOptix) using IonWizard 6.4 version 2 software
(IonOptix). The acquisition rate of calcium imaging was 100
points/s. The Fura-2 required dual-wavelength excitation at
340 nm and 380 nm, and the emission signals were recorded
at 505 nm. The calcium level was presented as a ratio of
340/380 nm (F340/380) and calibrated with amount of free
calcium (nmol/L). The calcium transients of every cardiomy-
ocyte were recorded with background subtraction.
Statistical Analysis
Continuous variables are expressed as meanSEM. Statistical
comparisons between 2 groups were performed using Student
t test or nonparametric Mann-Whitney test (for n<10). For
analysis involving more than 2 groups, 1-way ANOVA analysis
was used. For posttest, Tukey analysis was used to compare
all pairs of columns. A P value <0.05 was considered
statistically signiﬁcant.
Results
Patient Characteristics, Generation of LMNA-
Mutation-Harboring hiPSCs, and Cardiac
Differentiation
Two patients with nonsense LMNA mutations and 1 patient
with a frame-shift mutation were recruited to the study. The
ﬁrst patient was a 49-year old Chinese man who initially
presented with atrial ﬁbrillation and complete atrioventricular
block and required permanent cardiac pacemaker implanta-
tion. Two years later, he developed sustained ventricular
tachyarrhythmia and heart failure with an impaired left
ventricular ejection fraction of 35%. An automatic implantable
cardioverter deﬁbrillator was therefore implanted (Table). His
family history was remarkable for complete atrioventricular
block and sudden cardiac death. Sequencing of the LMNA
gene revealed a heterozygous single-base exchange (672G?
T) in exon 4, resulting in an R225X nonsense mutation
Table. Cardiac Manifestations in Affected Subjects Bearing LMNA Mutations
LMNA
Mutations Sex
Cardiac Manifestations (Age of Manifestation)
Complete
Heart Block AF VT/VF
Dilated
Cardiomyopathy AICD
R225X M + (49) + (49) + (50) + (51) + (52)
Q354X M + (50) + (50) + (56) + (50) + (50)
T518fs M + (43) + (43) + (47) + (47) + (47)
AF indicates atrial ﬁbrillation; AICD, automatic implantable cardioverter deﬁbrillator; VT/VF, ventricular tachycardia/ventricular ﬁbrillation.
“+” represent presence of disease phenotype, while the ages of disease onset are shown the brackets.
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(truncation in the coil 1B domain of both lamin A and C
proteins), previously known to be associated with familial
dilated cardiomyopathy18,27,28 (Figure 1A and 1B). The sec-
ond patient was a 50-year old Chinese man who also had
atrial ﬁbrillation, complete atrioventricular block, ventricular
tachyarrhythmia, and heart failure. Of his 4 siblings, 3 had
similar cardiac conditions, and all had had an automatic
implantable cardioverter deﬁbrillator implanted. A heterozy-
gous single-base exchange (1062C?T) in exon 6 of the LMNA
gene resulting in a Q354X nonsense mutation was found to be
cosegregated with the cardiac phenotype in this family
(Figure 1). The last patient was a 43-year-old Chinese man
with atrial ﬁbrillation, complete atrioventricular block, and
ventricular tachyarrhythmia. A heterozygous single-base dele-
tion (1554delC) at exon 9 of the LMNA gene was detected.
According to our prediction of a second open reading frame
with 1 “C” deletion at codon position 1554 in the LMNA
mRNA transcript (NM_170707), the premature stop codon
with sequence of “TGA” will be generated at an earlier
position at the 547th amino acid, shortening the LMNA
protein that is supposed to be transcribed (reduced from 665
to 547 amino acids) (Figure S1). This patient’s paternal uncle
A
B
Figure 1. Schematic diagram illustrating the LMNA mutations involved in this study. A, Genetic
disorders caused by nonsense and frame-shift mutations in LMNA. R225X yielded a premature stop
codon, TGA, due to a C-to-T substitution; Q354X also yielded a premature stop codon, TAG, due to a C-to-T
substitution; and the frameshift mutation T518fs resulted from a C deletion. B, Splice variant of LMNA
gene yielding lamin A/C protein: the mutation yielded 3 different lengths of truncated lamin A/C protein.
Key: NLS indicates nuclear localization signal.
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had had atrial ﬁbrillation and complete atrioventricular block
(Figure 1A and 1B). Dermal ﬁbroblasts were obtained from
these patients during automatic implantable cardioverter
deﬁbrillator implantation, and patient-speciﬁc hiPSCs harbor-
ing the speciﬁc mutations were generated accordingly. The
patient-speciﬁc LMNA mutations in these hiPSCs had been
conﬁrmed by genomic DNA sequencing analysis. For simplic-
ity in description, the hiPSC lines containing the 672G?T,
1062C?T, and 1554delC mutations in 1 of the LMNA alleles
will be denoted as R225X, Q354X, and T518fs mutants,
respectively, in this article.
The commercially available hiPSC line (line IMR90, Wicell)
and KS1 hiPSC line generated by our lab by lentiviral
reprogramming that do not contain any LMNA mutations
was used as a wild-type control in this study 21 (Figure 1).
Effects of PTC124 on Expression of Lamin A/C
Proteins in Dermal Fibroblasts and hiPSC-Derived
Cardiomyocytes
First, we tested the effects of PTC124 on the level of lamin A/
C proteins in dermal ﬁbroblasts obtained from the 3 patients
Figure 2. Effects of PTC124 on the expression of lamin A/C proteins in dermal ﬁbroblasts and hiPSC-
derived cardiomyocytes (hiPSC-CMC) derived from wild-type (LMNAWT1/WT1 and LMNAWT2/WT2) and LMNA
mutants (LMNAR225X/WT, LMNAQ354X/WT, and LMNAT518fs/WT). A, Representative immunoblot and (B)
quantitative data of protein-normalized lamin A/C protein expression. The band intensities of lamin A/C
and b-actin (Actb) were measured from the high-resolution (3009300 dots per inch) images using Image J.
At least 3 to 6 independent samples were prepared for Western blot analysis. The signiﬁcant difference of
quantitative data was tested by 2-way ANOVA with post hoc Turkey multiple comparison test (**P<0.01 as
indicated by arrows; #P<0.05, Control vs PTC). Original images of immunoblots in individual experiments
are shown in Figure S2. hiPSC indicates human induced pluripotent stem cells.
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Figure 3. Nuclear blebbing in the hiPSC-derived cardiomyocytes. The 2 wild-type lines (LMNAWT1/WT1 and
LMNAWT2/WT2), R225X (LMNAR225X/WT), Q354X (LMNAQ354/WT), and T518fs (LMNAT518fs/WT),mutant hiPSC lineswere
differentiated into cardiomyocytes and treated with PTC124. The occurrence of cardiac nuclear blebbingwas revealed
with coimmunostaining of cardiac troponin T (red) and laminA/C (green). A, A single representative hiPSCCMC, and (B
through D) representative images of lower magniﬁcation were used to quantify the portion of nuclear blebbing in a
single ﬁeld. At least 3 countings were performed. E, Quantitative data of nuclear blebbing count. The signiﬁcant
difference of quantitative data was tested by 2-way ANOVA with post hoc Turkey multiple comparison test
(****P<0.0001 as indicated by arrows; ####P<0.0001 control vs treatment group). cTnT indicates cardiac troponin-T;
DAPI, 4,6-diamidino-2-phenylindole dihydrochloride; hiPSC, human induced pluripotent stem cells; LMNA, lamin.
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with LMNA-related cardiomyopathy (Figure 2). Dermal ﬁbrob-
lasts were treated with PTC124 (50 lmol/L), and the lamin
A/C protein levels were evaluated by Western blotting
analysis. In the absence of PTC124, the translation yielded
only intact lamin A/C products: a 74-kDa band indicating
lamin A protein and a 63-kDa band from lamin C protein, in
Figure 3. Continued
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dermal ﬁbroblasts from all 3 patients. No truncated lamin A/C
protein was detected in any of the mutant lines (data not
shown) (Figure 2). Compared with their wild-type counterpart,
the levels of lamin A/C proteins were markedly reduced in
dermal ﬁbroblasts from all mutant lines. Treatment with
PTC124 increased the level of both lamin A and C isoforms in
dermal ﬁbroblasts carrying the R225X mutation in the LMNA
gene but not in the wild-type or dermal ﬁbroblasts from the
other 2 patients harboring Q354X or T518fs mutations.
Importantly, as no prolonged lamin A/C protein products were
detected, PTC124 treatment was not likely causing normal
termination codon read-through.
Similar results were observed in the hiPSC-derived car-
diomyocytes treated with PTC124. In brief, the level of lamin
A/C proteins in all 3 mutant lines was substantially reduced
compared with their wild-type counterpart in the absence of
PTC124 (Figure 2). Similar to the ﬁndings observed in dermal
ﬁbroblasts, PTC124 treatment increased the level of both
lamin A and C proteins in cardiomyocytes derived from the
R225X mutant hiPSC line but not in those of the other 2
LMNA mutations (ie, Q354X and T518fs mutants). Interest-
ingly, mild accumulation of prelamin A was observed in the
cardiomyocytes derived from Q354X and T518fs mutants
(Figure 2), regardless of the presence of PTC124 treatment.
Effects of PTC124 on Electrical Stimulation–
Induced Nuclear Senescence and Apoptosis in
hiPSC-Derived Cardiomyocytes
As previously reported by our team18 and others,29 the nuclei
of cardiomyocytes from LMNA-related cardiomyopathy often
exhibit dysmorphic features such as micronucleation (bleb-
bing), one of the hallmarks of nuclear senescence.30 These
changes together with apoptosis are often exaggerated in
cardiomyocytes that are electrically active29 or under con-
stant electrical stress.18 As shown in Figure 3, coimmunos-
taining of lamin A/C (green) and cardiac troponin-T (red)
revealed that the cardiomyocytes derived from R225X or
T518fs mutant lines exhibited nuclear blebbing even in the
absence of external stress. After continuous electrical
stressing, the nuclear blebbing events became more frequent
in all the hiPSC-derived cardiomyocytes carrying LMNA
mutations. Interestingly, the application of PTC124 alleviated
nuclear senescent morphological abnormalities in the car-
diomyocytes derived from the R225X mutant but not in those
derived from the Q354X or T518fs mutant lines (Figure 3A
through 3D). To evaluate the effects of PTC124 on apoptosis,
we ﬁrst performed TUNEL analysis. As shown in Figure 4A
through 4D, in concordance with the nuclear blebbing assay,
the electrical stress-induced apoptosis in cardiomyocytes with
R225X mutation was markedly reduced in the presence of
PTC124 (Figure 4B). Nonetheless, no signiﬁcant changes in
apoptosis were detected on application of PTC124 in the
other 2 mutants (Figure 4C through 4D). In order to provide
more quantitative assessment of the protective effects of
PTC124 against electrical stress-induced apoptosis, we
further quantiﬁed the proportion of apoptotic cells using the
APO-BrdU TUNEL assay (Figure 4F through 4G and Table S1).
Compared with the wild-type control, all 3 mutants showed a
signiﬁcantly higher proportion of apoptotic cardiomyocytes.
On electrical stressing, the proportion of apoptotic cells
increased markedly by 40.58% (n=3-7, P<0.05) only in hiPSC-
derived cardiomyocytes with the R225X mutation (Figure 4G).
More importantly, application of PTC124 signiﬁcantly reduced
the electrical stimulation-induced apoptotic population by
41.89% in cardiomyocytes derived from R225X mutant (n=3-
5; P<0.05). Neither electrical stress nor the application of
PTC124 caused any statistically signiﬁcant changes to the
proportion of apoptotic cells in any of the other groups.
Nonsense LMNA mRNA Degradation
In addition to defective translation as a result of the
nonsense mutations, the suppressed production of lamin
Figure 3. Continued
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Figure 4. Evaluation of TUNEL-positive apoptotic cell in electrically stressed and PTC124-treated cardiomyocytes
derived from wild-type (LMNAWT1/WT1 and LMNAWT2/WT2) and LMNA mutants (LMNAR225X/WT, LMNAQ354X/WT, and
LMNAT518fs/WT) by (A through E) immunostaining; (F throughG) and also byApo-BrdU TUNEL-FACS analysis to quantify
apoptotic cells (Signiﬁcant difference was analyzed by 2-way ANOVA with Tukey multiple comparison post-hoc test
*P<0.05; n=3 to 5 (as indicted by arrows) and (control vs electrically stressed) #P<0.05; n=3 to 7). FACS indicates
ﬂuorescence-activated cell sorting; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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A/C proteins could be due to a nonsense-mediated mRNA
decay mechanism.31 To evaluate such a possibility, we
precisely quantiﬁed the LMNA mRNA level in cardiomyocytes
derived from the wild-type and mutant lines using Taqman
real-time polymerase chain reaction assay. As shown in
Figure 5, the relative cardiac LMNA expression in all 3
Figure 4. Continued
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mutants was signiﬁcantly lower than that in the wild-type
control. This suggests that nonsense mRNA degradation may
contribute to the reduced lamin A/C protein level.
Interestingly, PTC124 could not restore the mRNA production
in any mutant line, suggesting that its activity was limited to
a translational level.
Figure 4. Continued
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Effects of PTC124 on Excitation-Contraction
Coupling in Cardiomyocytes Derived From the
R225X Mutant hiPSC
Because the PTC124-mediated reduction in apoptosis was
observed only in the cardiomyocytes derived from the R225X
mutant and not in other lines, we further evaluated the effects
of PTC124 on excitation-contraction coupling, calcium home-
ostasis, and contractile abnormalities in this particular line.
Contractilities and calcium transients were recorded
simultaneously under ﬁeld electrical pacing at frequencies
ranging from 0.5 Hz to 2 Hz. As shown in Figure 6A, hiPSC-
derived cardiomyocytes (both wild-type and mutants) were
responsive to electrical pacing and showed comparable
diastolic and peak calcium levels (Figure 6B and 6D). Diastolic
calcium levels (indicated by the baseline levels of the calcium
transient tracings) of both lines increased as the pacing
frequency increased (Figure 6B). In general, the maximum
calcium released (indicated by the peak amplitude of the
calcium transient tracings) in cardiomyocytes derived from
the R225X mutant was less than that released in the wild-type
counterparts (Figure 6C). The systolic cell length also reduced
remarkably in the mutant cardiomyocytes treated with
PTC124, indicating a more efﬁcient coupling between intra-
cellular calcium surge and cellular contraction (Figure 6E).
Regardless of the application of PTC124, there was no
signiﬁcant change in the upstroke velocity (ie, the rate of
calcium release) of calcium transients or rate of cell
shortening between wild-type and mutant hiPSC-derived
cardiomyocytes (Figure 6F and 6G). Nevertheless, at high
pacing speed (2 Hz), PTC124 signiﬁcantly improved the rate
of calcium reuptake in the mutant cardiomyocytes (as
indicated by a more negative value of Vmax decay) (P<0.05,
n=3) (Figure 6H). Furthermore, PTC124 treatment appeared
to improve the rate of cellular relengthening in the mutant
cardiomyocytes (Figure 6I).
Discussion
Precision medicine, according to the National Institutes of
Health in the United States, is an emerging approach for
disease treatment and prevention that takes into account
Figure 4. Continued
Figure 5. Normalized gene expression level of LMNA in
PTC124-treated hiPSC-derived cardiomyocytes. The endogenous
control gene was TUBB, and TNNT2 was used to normalize the
number of cardiac cells within the differentiated population.
Signiﬁcant difference was analyzed by 1-way ANOVA with Tukey
multiple comparison post hoc test compared with wild-type
control group, *P<0.05 and **P<0.01; n=5. hiPSC indicates
human induced pluripotent stem cells.
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Figure 6. Excitation-contraction (EC) coupling was improved by PTC124 in the cardiomyocytes
derived from theR255Xmutant.A,Representative tracingof calcium transient andcell-shortening in
LMNAWT/WT and LMNAR225X/WT cells treated with PTC124. Rate dependence of calcium transients
and cell contractility pacing frequency range of 0.5, 1, and 1.5 to 2 Hz are shown in terms of (B)
diastolic calcium, (C) peak calcium amplitude, (D) fractional shortening (%) (*P<0.05; n=5 to 7; WT:
PTC vs R225X:PTC ####P<0.0001; R225X: 0.5-Hz control vs R225X: 0.5-Hz or 1-Hz PTC: φ φ φ φ
P<0.0001;R225X:0.5 HzPTCvsR225X:1.5or 2 HzPTC:φφP<0.001); (EandF)maximal upstroke
velocity (Vmax upstroke) of calcium transient and rate of cell shortening (ie, contraction); (G and H)
maximal decay velocity (Vmax decay) and rate of cell relengthening (ie relaxation). Improved calcium
decay kinetics and relaxation performance are shown (G andH). Signiﬁcant differencewas analyzed
by comparing pacing rate of 0.5 Hzwith the other rates of the same treatment group in 1 cell line, or
otherwise indicated by arrows using 2-way ANOVA with Turkey test as post hoc (*P<0.05).
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individual variability in environment, lifestyle, and genetic
makeup for individual patients.32,33 The assumption is that
differences in an individual patient’s genetic makeup as well
as environmental factors contribute to his or her differential
clinical outcome, particularly in responsiveness to treatments.
In other words, patients with apparently similar clinical
conditions may be treated differently because of these
individual differences. Over the past 3 decades, there has
been tremendous progress in genetics research that has
identiﬁed numerous genes responsible for dilated cardiomy-
opathies and provided novel insight into their pathogenic
mechanisms. Nonetheless, translation of these research
ﬁndings to clinical practice remains incomplete. In fact, even
with the availability of an individual patient’s genetic infor-
mation that underlies dilated cardiomyopathies, a disease-
speciﬁc intervention designed to tackle the root causes of the
condition is rarely available. As a result, despite different
genetic etiologies and pathogeneses, dilated cardiomy-
opathies are often treated similarly simply based on clinical
presentations.
Mutations in LMNA genes are the most common cause of
familial dilated cardiomyopathy, particularly among those with
concomitant atrioventricular conduction block.7,8 In our study,
despite different mutations in the 3 patients with LMNA-
related cardiomyopathy, their clinical presentations were
remarkably similar with early onset atrioventricular block
and atrial ﬁbrillation around the fourth decade of life, followed
by ventricular tachyarrhythmia and heart failure in the ﬁfth to
sixth decade of life. The condition was inherited in an
autosomal dominant pattern in all 3 families. In accordance
with their genotypes, both dermal ﬁbroblasts and cardiomy-
ocytes derived from R225X, Q354X, and T518fs mutants
displayed reduced lamin A/C protein production. As demon-
strated in our previous hiPSC-based model of LMNA-related
cardiomyopathy,18 cardiomyocytes derived from these 3
mutants exhibited nuclear senescence and apoptosis that
were aggravated in the presence of electrical stress.
Nonetheless, despite their very similar clinical presentations
and cellular phenotypes, there was a differential effect of
PTC124 on lamin A/C protein production in their primary
dermal ﬁbroblasts (R225X>>Q354X and T518fs). Similar to
dermal ﬁbroblasts, PTC124 restored lamin A/C protein
production only in cardiomyocytes derived from the R225X
mutants but not in their Q354X or T518fs counterparts. More
importantly, the increase in lamin A/C production was
associated with alleviated nuclear senescence and reduced
apoptosis. Furthermore, PTC124 treatment improved the
excitation-contraction coupling and contractile functions of
the hiPSC-derived cardiomyocytes carrying the R225X
mutation.
The lack of responsiveness to PTC124 of cardiomyocytes
derived from the T518fs mutant, which served as a negative
control, is expected. On the contrary, for the cardiomyocytes
derived from the Q354X mutant, the lack of efﬁciency could
be explained by the difference in nucleotide sequence of the
mutant premature stop codons. Nonsense mutations are
Figure 6. Continued
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point mutations that result in the occurrence of 1 of 3 stop
codons, UAG, UAA, or UGA, in the messenger RNA coding
region, leading to a truncated protein product due to
premature termination of mRNA translation and/or promotion
of mRNA destabilization by nonsense-mediated mRNA decay.
Although PTC124 promotes read-through of all 3 nonsense
codons, its potency differs according to the nucleotide
sequences of the premature stop codons, with the highest
read-through at UGA, followed by UAG, and then UAA.10 For
the 2 nonsense mutations, the R225X mutation in the LMNA
gene is a result of a premature stop codon (UGA) that is the
most PTC124-responsive nucleotide sequence, whereas in
the Q354X mutant, the sequence of the stop codon is UAG,
which seems to be less PTC124 responsive. Because the
efﬁcacy of the translational read-through of premature stop
codons and production of full-length proteins by interfering
with ribosomal proofreading depend on the availability of
nonsense transcripts to the ribosomal translational machin-
ery, it is interesting that in our study, application of PTC124
increased mRNA expression of the 2 nonsense transcripts:
R225X and Q354X. Nonetheless, it is beyond the scope of the
present study to determine whether PTC124 can affect the
efﬁciency of the nonsense mutation mRNA decay mecha-
nisms.
For nonsense mutation, it seems to be stating the obvious
that translational read-through of premature stop codons with
PTC124 is expected to produce full-length proteins and
reverse the pathogenic process. Nonetheless, in a recent
study using hiPSC-derived cardiomyocytes from 2 patients
who harbored nonsense mutations in the sodium channel
gene SCN5A, R1638X and W156X, although the premature
stop codon sequences in both mutations were the most
optimum sequence for PTC124, UGA, PTC124 and gentam-
icin, another premature stop codon read-through agent, failed
to restore sodium current INa.
34 Although the sodium channel
protein level was not quantiﬁed to document the restored
protein translation, other downstream mechanisms such as a
trafﬁcking defect might have been responsible. This reinforces
the need for precision medicine. hiPSC technology and in vitro
drug testing strategies provide unparalleled opportunities to
realize the promise of precision medicine. This strategy may
be exploited to select the patients with maximum drug
responsiveness for standard clinical trials. Then, the expected
drug effects may be much larger, and the required sample size
would then be much smaller, making standard randomized
clinical trials possible.
Conclusions
Taken collectively, PTC124 promoted translation read-through
of premature stop codons in patient-speciﬁc hiPSC-derived
cardiomyocytes that harbored the mutation R225X in the
LMNA gene and alleviated nuclear senescence, apoptosis, and
altered excitation-contraction coupling. The same effects
were not evident in patient-speciﬁc hiPSC-derived cardiomy-
ocytes that harbored another nonsense mutation or a
frame-shift mutation. Based on our data, hiPSC technology
represents a general approach to predict the clinical response
of patients with an apparently similar clinical condition and to
realize the potential of precision medicine.
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Table S1. Raw data of apoptotic assay of the effects of PTC124 on electrically-
stressed hiPSC-CMs by Apo-BrdU-TUNEL FACS analysis
Cell line Treatment group Number of cell % of Apoptotic cell 
Total Apoptotic  
(TUNEL-positive) 
LMNAWT/WT Control 1655 136 8.20 
1604 113 7.00 
1181 134 11.30 
650 72 11.10 
1505 211 14.00 
1546 140 9.10 
2457 129 5.30 
Electrically stressed 693 129 18.80 
8679 132 1.50 
1265 60 4.70 
Electrically stressed + 
PTC124 
776 10 14.20 
1360 10 0.70 
8640 210 2.40 
LMNAR225X/WT Control 1587 132 8.30 
4923 1653 38.50 
260 132 50.80 
2736 291 10.60 
3973 343 8.60 
692 131 18.90 
1532 826 53.90 
Electrically stressed 3642 1547 42.50 
272 196 72.10 
2062 1822 88.40 
Electrically stressed + 
PTC124 
272 196 37.10 
2293 415 18.10 
8282 1572 19.00 
875 168 19.20 
152 54 35.50 
LMNAQ354X/WT Control 689 75 10.90 
953 108 11.30 
395 54 13.70 
278 198 71.20 
2003 565 28.90 
1909 311 16.30 
593 75 12.60 
1385 533 38.50 
Electrically stressed 149 110 73.80 
2780 625 22.50 
1052 350 33.30 
Electrically stressed + 
PTC124 
900 314 34.90 
1615 453 28.00 
2500 750 30.00 
LMNAT518fs/WT Control 128 97 75.80 
220 124 56.40 
2266 1708 75.40 
 1474 332 22.50 
1200 286 23.80 
Electrically stressed 608 321 52.80 
3549 543 15.30 
1426 342 24.00 
Electrically stressed + 
PTC124 
261 207 79.30 
2255 413 18.30 
1152 415 36.00 
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Figure S1.  
 
 
  
Yellow: Start codon 
Blue: Frameshift mutation site due to deletion 
Red: Stop codon 
A 
>ORF1 
 
1     atg gag acc ccg tcc cag cgg cgc gcc acc cgc agc ggg gcg cag   45 
1     Met Glu Thr Pro Ser Gln Arg Arg Ala Thr Arg Ser Gly Ala Gln   15 
 
46    gcc agc tcc act ccg ctg tcg ccc acc cgc atc acc cgg ctg cag   90 
16    Ala Ser Ser Thr Pro Leu Ser Pro Thr Arg Ile Thr Arg Leu Gln   30 
 
91    gag aag gag gac ctg cag gag ctc aat gat cgc ttg gcg gtc tac   135 
31    Glu Lys Glu Asp Leu Gln Glu Leu Asn Asp Arg Leu Ala Val Tyr   45 
 
136   atc gac cgt gtg cgc tcg ctg gaa acg gag aac gca ggg ctg cgc   180 
46    Ile Asp Arg Val Arg Ser Leu Glu Thr Glu Asn Ala Gly Leu Arg   60 
 
181   ctt cgc atc acc gag tct gaa gag gtg gtc agc cgc gag gtg tcc   225 
61    Leu Arg Ile Thr Glu Ser Glu Glu Val Val Ser Arg Glu Val Ser   75 
 
226   ggc atc aag gcc gcc tac gag gcc gag ctc ggg gat gcc cgc aag   270 
76    Gly Ile Lys Ala Ala Tyr Glu Ala Glu Leu Gly Asp Ala Arg Lys   90 
 
271   acc ctt gac tca gta gcc aag gag cgc gcc cgc ctg cag ctg gag   315 
91    Thr Leu Asp Ser Val Ala Lys Glu Arg Ala Arg Leu Gln Leu Glu   105 
 
316   ctg agc aaa gtg cgt gag gag ttt aag gag ctg aaa gcg cgc aat   360 
106   Leu Ser Lys Val Arg Glu Glu Phe Lys Glu Leu Lys Ala Arg Asn   120 
 
361   acc aag aag gag ggt gac ctg ata gct gct cag gct cgg ctg aag   405 
121   Thr Lys Lys Glu Gly Asp Leu Ile Ala Ala Gln Ala Arg Leu Lys   135 
 
406   gac ctg gag gct ctg ctg aac tcc aag gag gcc gca ctg agc act   450 
136   Asp Leu Glu Ala Leu Leu Asn Ser Lys Glu Ala Ala Leu Ser Thr   150 
 
451   gct ctc agt gag aag cgc acg ctg gag ggc gag ctg cat gat ctg   495 
151   Ala Leu Ser Glu Lys Arg Thr Leu Glu Gly Glu Leu His Asp Leu   165 
 
496   cgg ggc cag gtg gcc aag ctt gag gca gcc cta ggt gag gcc aag   540 
166   Arg Gly Gln Val Ala Lys Leu Glu Ala Ala Leu Gly Glu Ala Lys   180 
 
541   aag caa ctt cag gat gag atg ctg cgg cgg gtg gat gct gag aac   585 
181   Lys Gln Leu Gln Asp Glu Met Leu Arg Arg Val Asp Ala Glu Asn   195 
 
586   agg ctg cag acc atg aag gag gaa ctg gac ttc cag aag aac atc   630 
196   Arg Leu Gln Thr Met Lys Glu Glu Leu Asp Phe Gln Lys Asn Ile   210 
 
631   tac agt gag gag ctg cgt gag acc aag cgc cgt cat gag acc cga   675 
211   Tyr Ser Glu Glu Leu Arg Glu Thr Lys Arg Arg His Glu Thr Arg   225 
 
676   ctg gtg gag att gac aat ggg aag cag cgt gag ttt gag agc cgg   720 
226   Leu Val Glu Ile Asp Asn Gly Lys Gln Arg Glu Phe Glu Ser Arg   240 
 
721   ctg gcg gat gcg ctg cag gaa ctg cgg gcc cag cat gag gac cag   765 
241   Leu Ala Asp Ala Leu Gln Glu Leu Arg Ala Gln His Glu Asp Gln   255 
 
766   gtg gag cag tat aag aag gag ctg gag aag act tat tct gcc aag   810 
811   ctg gac aat gcc agg cag tct gct gag agg aac agc aac ctg gtg   855 
271   Leu Asp Asn Ala Arg Gln Ser Ala Glu Arg Asn Ser Asn Leu Val   285 
 
856   ggg gct gcc cac gag gag ctg cag cag tcg cgc atc cgc atc gac   900 
286   Gly Ala Ala His Glu Glu Leu Gln Gln Ser Arg Ile Arg Ile Asp   300 
 
901   agc ctc tct gcc cag ctc agc cag ctc cag aag cag ctg gca gcc   945 
301   Ser Leu Ser Ala Gln Leu Ser Gln Leu Gln Lys Gln Leu Ala Ala   315 
 
946   aag gag gcg aag ctt cga gac ctg gag gac tca ctg gcc cgt gag   990 
316   Lys Glu Ala Lys Leu Arg Asp Leu Glu Asp Ser Leu Ala Arg Glu   330 
 
991   cgg gac acc agc cgg cgg ctg ctg gcg gaa aag gag cgg gag atg   1035 
331   Arg Asp Thr Ser Arg Arg Leu Leu Ala Glu Lys Glu Arg Glu Met   345 
 
1036  gcc gag atg cgg gca agg atg cag cag cag ctg gac gag tac cag   1080 
346   Ala Glu Met Arg Ala Arg Met Gln Gln Gln Leu Asp Glu Tyr Gln   360 
 
1081  gag ctt ctg gac atc aag ctg gcc ctg gac atg gag atc cac gcc   1125 
361   Glu Leu Leu Asp Ile Lys Leu Ala Leu Asp Met Glu Ile His Ala   375 
 
1126  tac cgc aag ctc ttg gag ggc gag gag gag agg cta cgc ctg tcc   1170 
376   Tyr Arg Lys Leu Leu Glu Gly Glu Glu Glu Arg Leu Arg Leu Ser   390 
 
1171  ccc agc cct acc tcg cag cgc agc cgt ggc cgt gct tcc tct cac   1215 
391   Pro Ser Pro Thr Ser Gln Arg Ser Arg Gly Arg Ala Ser Ser His   405 
 
1216  tca tcc cag aca cag ggt ggg ggc agc gtc acc aaa aag cgc aaa   1260 
406   Ser Ser Gln Thr Gln Gly Gly Gly Ser Val Thr Lys Lys Arg Lys   420 
 
1261  ctg gag tcc act gag agc cgc agc agc ttc tca cag cac gca cgc   1305 
421   Leu Glu Ser Thr Glu Ser Arg Ser Ser Phe Ser Gln His Ala Arg   435 
 
1306  act agc ggg cgc gtg gcc gtg gag gag gtg gat gag gag ggc aag   1350 
436   Thr Ser Gly Arg Val Ala Val Glu Glu Val Asp Glu Glu Gly Lys   450 
 
1351  ttt gtc cgg ctg cgc aac aag tcc aat gag gac cag tcc atg ggc   1395 
451   Phe Val Arg Leu Arg Asn Lys Ser Asn Glu Asp Gln Ser Met Gly   465 
 
1396  aat tgg cag atc aag cgc cag aat gga gat gat ccc ttg ctg act   1440 
466   Asn Trp Gln Ile Lys Arg Gln Asn Gly Asp Asp Pro Leu Leu Thr   480 
 
1441  tac cgg ttc cca cca aag ttc acc ctg aag gct ggg cag gtg gtg   1485 
481   Tyr Arg Phe Pro Pro Lys Phe Thr Leu Lys Ala Gly Gln Val Val   495 
 
1486  acg atc tgg gct gca gga gct ggg gcc acc cac agc ccc cct acc   1530 
496   Thr Ile Trp Ala Ala Gly Ala Gly Ala Thr His Ser Pro Pro Thr   510 
                                      T518  
1531  gac ctg gtg tgg aag gca cag aac acc tgg ggc tgc ggg aac agc   1575 
511   Asp Leu Val Trp Lys Ala Gln Asn Thr Trp Gly Cys Gly Asn Ser   525 
 
1576  ctg cgt acg gct ctc atc aac tcc act ggg gaa gaa gtg gcc atg   1620 
526   Leu Arg Thr Ala Leu Ile Asn Ser Thr Gly Glu Glu Val Ala Met   540 
 
526   Leu Arg Thr Ala Leu Ile Asn Ser Thr Gly Glu Glu Val Ala Met   540 
 
1621  cgc aag ctg gtg cgc tca gtg act gtg gtt gag gac gac gag gat   1665 
541   Arg Lys Leu Val Arg Ser Val Thr Val Val Glu Asp Asp Glu Asp   555 
 
1666  gag gat gga gat gac ctg ctc cat cac cac cac ggc tcc cac tgc   1710 
556   Glu Asp Gly Asp Asp Leu Leu His His His His Gly Ser His Cys   570 
 
1711  agc agc tcg ggg gac ccc gct gag tac aac ctg cgc tcg cgc acc   1755 
571   Ser Ser Ser Gly Asp Pro Ala Glu Tyr Asn Leu Arg Ser Arg Thr   585 
 
1756  gtg ctg tgc ggg acc tgc ggg cag cct gcc gac aag gca tct gcc   1800 
586   Val Leu Cys Gly Thr Cys Gly Gln Pro Ala Asp Lys Ala Ser Ala   600 
 
1801  agc ggc tca gga gcc cag gtg ggc gga ccc atc tcc tct ggc tct   1845 
601   Ser Gly Ser Gly Ala Gln Val Gly Gly Pro Ile Ser Ser Gly Ser   615 
 
1846  tct gcc tcc agt gtc acg gtc act cgc agc tac cgc agt gtg ggg   1890 
616   Ser Ala Ser Ser Val Thr Val Thr Arg Ser Tyr Arg Ser Val Gly   630 
 
1891  ggc agt ggg ggt ggc agc ttc ggg gac aat ctg gtc acc cgc tcc   1935 
631   Gly Ser Gly Gly Gly Ser Phe Gly Asp Asn Leu Val Thr Arg Ser   645 
 
1936  tac ctc ctg ggc aac tcc agc ccc cga acc cag agc ccc cag aac   1980 
646   Tyr Leu Leu Gly Asn Ser Ser Pro Arg Thr Gln Ser Pro Gln Asn   660 
 
1981  tgc agc atc atg taa   1995 
661   Cys Ser Ile Met End   665 
 
256   Val Glu Gln Tyr Lys Lys Glu Leu Glu Lys Thr Tyr Ser Ala Lys   270 
 
Translation of LMNA wild type transcript (NM_170707)  
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541   Ala Ser Trp Cys Ala Gln End Leu Trp Leu Arg Thr Thr Arg Met   555 
271   Leu Asp Asn Ala Arg Gln Ser Ala Glu Arg Asn Ser Asn Leu Val   285 
 
856   ggg gct gcc cac gag gag ctg cag cag tcg cgc atc cgc atc gac   900 
286   Gly Ala Ala His Glu Glu Leu Gln Gln Ser Arg Ile Arg Ile Asp   300 
 
901   agc ctc tct gcc cag ctc agc cag ctc cag aag cag ctg gca gcc   945 
301   Ser Leu Ser Ala Gln Leu Ser Gln Leu Gln Lys Gln Leu Ala Ala   315 
 
946   aag gag gcg aag ctt cga gac ctg gag gac tca ctg gcc cgt gag   990 
316   Lys Glu Ala Lys Leu Arg Asp Leu Glu Asp Ser Leu Ala Arg Glu   330 
 
991   cgg gac acc agc cgg cgg ctg ctg gcg gaa aag gag cgg gag atg   1035 
331   Arg Asp Thr Ser Arg Arg Leu Leu Ala Glu Lys Glu Arg Glu Met   345 
 
1036  gcc gag atg cgg gca agg atg cag cag cag ctg gac gag tac cag   1080 
346   Ala Glu Met Arg Ala Arg Met Gln Gln Gln Leu Asp Glu Tyr Gln   360 
 
1081  gag ctt ctg gac atc aag ctg gcc ctg gac atg gag atc cac gcc   1125 
361   Glu Leu Leu Asp Ile Lys Leu Ala Leu Asp Met Glu Ile His Ala   375 
 
1126  tac cgc aag ctc ttg gag ggc gag gag gag agg cta cgc ctg tcc   1170 
376   Tyr Arg Lys Leu Leu Glu Gly Glu Glu Glu Arg Leu Arg Leu Ser   390 
 
1171  ccc agc cct acc tcg cag cgc agc cgt ggc cgt gct tcc tct cac   1215 
391   Pro Ser Pro Thr Ser Gln Arg Ser Arg Gly Arg Ala Ser Ser His   405 
 
1216  tca tcc cag aca cag ggt ggg ggc agc gtc acc aaa aag cgc aaa   1260 
406   Ser Ser Gln Thr Gln Gly Gly Gly Ser Val Thr Lys Lys Arg Lys   420 
 
1261  ctg gag tcc act gag agc cgc agc agc ttc tca cag cac gca cgc   1305 
421   Leu Glu Ser Thr Glu Ser Arg Ser Ser Phe Ser Gln His Ala Arg   435 
 
1306  act agc ggg cgc gtg gcc gtg gag gag gtg gat gag gag ggc aag   1350 
436   Thr Ser Gly Arg Val Ala Val Glu Glu Val Asp Glu Glu Gly Lys   450 
 
1351  ttt gtc cgg ctg cgc aac aag tcc aat gag gac cag tcc atg ggc   1395 
451   Phe Val Arg Leu Arg Asn Lys Ser Asn Glu Asp Gln Ser Met Gly   465 
 
1396  aat tgg cag atc aag cgc cag aat gga gat gat ccc ttg ctg act   1440 
466   Asn Trp Gln Ile Lys Arg Gln Asn Gly Asp Asp Pro Leu Leu Thr   480 
 
1441  tac cgg ttc cca cca aag ttc acc ctg aag gct ggg cag gtg gtg   1485 
481   Tyr Arg Phe Pro Pro Lys Phe Thr Leu Lys Ala Gly Gln Val Val   495 
 
1486  acg atc tgg gct gca gga gct ggg gcc acc cac agc ccc cct acc   1530 
496   Thr Ile Trp Ala Ala Gly Ala Gly Ala Thr His Ser Pro Pro Thr   510 
                                    c.1554delC; p.T518fs  
1531  gac ctg gtg tgg aag gca cag aac act ggg gct gcg gga aca gcc   1575 
511   Asp Leu Val Trp Lys Ala Gln Asn Thr Gly Ala Ala Gly Thr Ala   525 
 
 
1577  tgc gta cgg ctc tca tca act cca ctg ggg aag aag tgg cca tgc   1621 
526   Cys Val Arg Leu Ser Ser Thr Pro Leu Gly Lys Lys Trp Pro Cys   540 
 
1622  gca agc tgg tgc gct cag tga ctg tgg ttg agg acg acg agg atg   1666 
541   Ala Ser Trp Cys Ala Gln End Leu Trp Leu Arg Thr Thr Arg Met   555 
 
>ORF1_NM170707 
 
1     atg gag acc ccg tcc cag cgg cgc gcc acc cgc agc ggg gcg cag   45 
1     Met Glu Thr Pro Ser Gln Arg Arg Ala Thr Arg Ser Gly Ala Gln   15 
 
46    gcc agc tcc act ccg ctg tcg ccc acc cgc atc acc cgg ctg cag   90 
16    Ala Ser Ser Thr Pro Leu Ser Pro Thr Arg Ile Thr Arg Leu Gln   30 
 
91    gag aag gag gac ctg cag gag ctc aat gat cgc ttg gcg gtc tac   135 
31    Glu Lys Glu Asp Leu Gln Glu Leu Asn Asp Arg Leu Ala Val Tyr   45 
 
136   atc gac cgt gtg cgc tcg ctg gaa acg gag aac gca ggg ctg cgc   180 
46    Ile Asp Arg Val Arg Ser Leu Glu Thr Glu Asn Ala Gly Leu Arg   60 
 
181   ctt cgc atc acc gag tct gaa gag gtg gtc agc cgc gag gtg tcc   225 
61    Leu Arg Ile Thr Glu Ser Glu Glu Val Val Ser Arg Glu Val Ser   75 
 
226   ggc atc aag gcc gcc tac gag gcc gag ctc ggg gat gcc cgc aag   270 
76    Gly Ile Lys Ala Ala Tyr Glu Ala Glu Leu Gly Asp Ala Arg Lys   90 
 
271   acc ctt gac tca gta gcc aag gag cgc gcc cgc ctg cag ctg gag   315 
91    Thr Leu Asp Ser Val Ala Lys Glu Arg Ala Arg Leu Gln Leu Glu   105 
 
316   ctg agc aaa gtg cgt gag gag ttt aag gag ctg aaa gcg cgc aat   360 
106   Leu Ser Lys Val Arg Glu Glu Phe Lys Glu Leu Lys Ala Arg Asn   120 
 
361   acc aag aag gag ggt gac ctg ata gct gct cag gct cgg ctg aag   405 
121   Thr Lys Lys Glu Gly Asp Leu Ile Ala Ala Gln Ala Arg Leu Lys   135 
 
406   gac ctg gag gct ctg ctg aac tcc aag gag gcc gca ctg agc act   450 
136   Asp Leu Glu Ala Leu Leu Asn Ser Lys Glu Ala Ala Leu Ser Thr   150 
 
451   gct ctc agt gag aag cgc acg ctg gag ggc gag ctg cat gat ctg   495 
151   Ala Leu Ser Glu Lys Arg Thr Leu Glu Gly Glu Leu His Asp Leu   165 
 
496   cgg ggc cag gtg gcc aag ctt gag gca gcc cta ggt gag gcc aag   540 
166   Arg Gly Gln Val Ala Lys Leu Glu Ala Ala Leu Gly Glu Ala Lys   180 
 
541   aag caa ctt cag gat gag atg ctg cgg cgg gtg gat gct gag aac   585 
181   Lys Gln Leu Gln Asp Glu Met Leu Arg Arg Val Asp Ala Glu Asn   195 
 
586   agg ctg cag acc atg aag gag gaa ctg gac ttc cag aag aac atc   630 
196   Arg Leu Gln Thr Met Lys Glu Glu Leu Asp Phe Gln Lys Asn Ile   210 
 
631   tac agt gag gag ctg cgt gag acc aag cgc cgt cat gag acc cga   675 
211   Tyr Ser Glu Glu Leu Arg Glu Thr Lys Arg Arg His Glu Thr Arg   225 
 
676   ctg gtg gag att gac aat ggg aag cag cgt gag ttt gag agc cgg   720 
226   Leu Val Glu Ile Asp Asn Gly Lys Gln Arg Glu Phe Glu Ser Arg   240 
 
721   ctg gcg gat gcg ctg cag gaa ctg cgg gcc cag cat gag gac cag   765 
241   Leu Ala Asp Ala Leu Gln Glu Leu Arg Ala Gln His Glu Asp Gln   255 
 
766   gtg gag cag tat aag aag gag ctg gag aag act tat tct gcc aag   810 
256   Val Glu Gln Tyr Lys Lys Glu Leu Glu Lys Thr Tyr Ser Ala Lys   270 
 
811   ctg gac aat gcc agg cag tct gct gag agg aac agc aac ctg gtg   855 
271   Leu Asp Asn Ala Arg Gln Ser Ala Glu Arg Asn Ser Asn Leu Val   285 
 
856   ggg gct gcc cac gag gag ctg cag cag tcg cgc atc cgc atc gac   900 
286   Gly Ala Ala His Glu Glu Leu Gln Gln Ser Arg Ile Arg Ile Asp   300 
 
901   agc ctc tct gcc cag ctc agc cag ctc cag aag cag ctg gca gcc   945 
301   Ser Leu Ser Ala Gln Leu Ser Gln Leu Gln Lys Gln Leu Ala Ala   315 
 
946   aag gag gcg aag ctt cga gac ctg gag gac tca ctg gcc cgt gag   990 
316   Lys Glu Ala Lys Leu Arg Asp Leu Glu Asp Ser Leu Ala Arg Glu   330 
 
991   cgg gac acc agc cgg cgg ctg ctg gcg gaa aag gag cgg gag atg   1035 
331   Arg Asp Thr Ser Arg Arg Leu Leu Ala Glu Lys Glu Arg Glu Met   345 
 
1036  gcc gag atg cgg gca agg atg cag cag cag ctg gac gag tac cag   1080 
346   Ala Glu Met Arg Ala Arg Met Gln Gln Gln Leu Asp Glu Tyr Gln   360 
 
1081  gag ctt ctg gac atc aag ctg gcc ctg gac atg gag atc cac gcc   1125 
361   Glu Leu Leu Asp Ile Lys Leu Ala Leu Asp Met Glu Ile His Ala   375 
 
1126  tac cgc aag ctc ttg gag ggc gag gag gag agg cta cgc ctg tcc   1170 
376   Tyr Arg Lys Leu Leu Glu Gly Glu Glu Glu Arg Leu Arg Leu Ser   390 
 
1171  ccc agc cct acc tcg cag cgc agc cgt ggc cgt gct tcc tct cac   1215 
391   Pro Ser Pro Thr Ser Gln Arg Ser Arg Gly Arg Ala Ser Ser His   405 
 
1216  tca tcc cag aca cag ggt ggg ggc agc gtc acc aaa aag cgc aaa   1260 
406   Ser Ser Gln Thr Gln Gly Gly Gly Ser Val Thr Lys Lys Arg Lys   420 
 
1261  ctg gag tcc act gag agc cgc agc agc ttc tca cag cac gca cgc   1305 
421   Leu Glu Ser Thr Glu Ser Arg Ser Ser Phe Ser Gln His Ala Arg   435 
 
1306  act agc ggg cgc gtg gcc gtg gag gag gtg gat gag gag ggc aag   1350 
436   Thr Ser Gly Arg Val Ala Val Glu Glu Val Asp Glu Glu Gly Lys   450 
 
1351  ttt gtc cgg ctg cgc aac aag tcc aat gag gac cag tcc atg ggc   1395 
451   Phe Val Arg Leu Arg Asn Lys Ser Asn Glu Asp Gln Ser Met Gly   465 
 
1396  aat tgg cag atc aag cgc cag aat gga gat gat ccc ttg ctg act   1440 
466   Asn Trp Gln Ile Lys Arg Gln Asn Gly Asp Asp Pro Leu Leu Thr   480 
 
1441  tac cgg ttc cca cca aag ttc acc ctg aag gct ggg cag gtg gtg   1485 
481   Tyr Arg Phe Pro Pro Lys Phe Thr Leu Lys Ala Gly Gln Val Val   495 
 
1486  acg atc tgg gct gca gga gct ggg gcc acc cac agc ccc cct acc   1530 
496   Thr Ile Trp Ala Ala Gly Ala Gly Ala Thr His Ser Pro Pro Thr   510 
                                    c.1554delC; p.T518fs  
1531  gac ctg gtg tgg aag gca cag aac act ggg gct gcg gga aca gcc   1575 
511   Asp Leu Val Trp Lys Ala Gln Asn Thr Gly Ala Ala Gly Thr Ala   525 
 
 
1577  tgc gta cgg ctc tca tca act cca ctg ggg aag aag tgg cca tgc   1621 
526   Cys Val Arg Leu Ser Ser Thr Pro Leu Gly Lys Lys Trp Pro Cys   540 
 
1622  gca agc tgg tgc gct cag tga ctg tgg ttg agg acg acg agg atg   1666 
541   Ala Ser Trp Cys Ala Gln End Leu Trp Leu Arg Thr Thr Arg Met   555 
 
Yellow: Start codon 
Blue: Frameshift mutation site due to deletion 
Red: Stop codon 
B Translation of LMNA T518 frameshit mutation transcript  
Premature stop codon  
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 Figure S2. A.  
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 Supplemental Figure Legends: 
 
Figure S1. Translational product of LMNA T518fs mutated transcript. (A) Wild type LMNA mRNA 
transcript (NM_170707); (B) Prediction of second open reading frame (ORF) with one “c” deletion at the 
1554th codon position in the LMNA mRNA transcript, the premature stop codon with sequence of “TGA” will 
be generated at an earlier position at the 547th amino acid, shortening of the Lmna protein that is supposed to be 
transcribed (reduced from the 665th to 547th amino acids). Moreover, even after PTC124 read-through, the 
amino acid sequence after frameshift mutation (the 519th amino acid) would be totally deviated from the native 
lamin A/C ones. 
 
Figure S2. Effects of PTC124 on the expression of lamin A/C proteins in dermal fibroblasts  (A-H) and 
hiPSC-derived cardiomyocytes (hiPSC-CMC) (I-M) derived from wild-type (LMNAWT1/WT1 & 
LMNAWT2/WT2) and LMNA mutants (LMNAR225X/WT, LMNAQ354X/WT and LMNAT518fs/WT). Original images 
of immunoblots with at least one wild type sample loaded on the same gel with patient samples. Lamin A/C 
(clone N18) were probed with antibody that recognized N-terminal, while beta-actin (ACTB) was used as the 
internal control for normalization of protein loading. Three to six independent samples were prepared for 
western blot analysis.  
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